At a glance
- Originator Eli Lilly and Company
- Class Antiasthmatics; Antirheumatics; Small molecules; Thiazolidines
- Mechanism of Action 5-lipoxygenase inhibitors; Antioxidants; Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 25 Feb 1999 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 04 May 1995 New profile
- 04 May 1995 Preclinical development for Rheumatic disorders in USA (Unknown route)